52 North Health secures £1m from SBRI Healthcare to advance its neutropenic sepsis test.
SBRI Healthcare backs Cambridge medical device developer with a Phase II award.
Cambridge-based medical device company developing point-of-care diagnostic tools for cancer patients. Its lead product is a portable system designed to assess neutropenic sepsis risk at home.
Cambridge-based medical device developer 52 North Health has secured £1m in new funding from SBRI Healthcare. The fresh capital will be directed towards finalising the development of its flagship NeutroCheck device, preparing for manufacturing, and conducting clinical usability trials.
The company is advancing its technology in collaboration with Macmillan Cancer Support and the UK Sepsis Trust to assist patients undergoing chemotherapy who face risks of neutropenic sepsis. Clinical evaluations will be anchored at Addenbrooke's Hospital as the firm moves closer to commercialisation.
From the founder
"We are privileged to have the support of the SBRI Healthcare programme and are committed to working with our world-leading collaborators to deliver on our ambitions to improve the care of cancer patients."
Saif Ahmad
Co-founder at 52 North Health
Investor perspective
"Neutropenic sepsis is a life-threatening condition and managing the risks can be very stressful for people with cancer, who are already dealing with all the challenges that a diagnosis can bring. But good care is a lifeline, not a luxury, and giving patients the tools to better manage their care can be a key component to helping to improve their quality of life."
Tanya Humphreys
Head of Impact Investments, Macmillan Cancer Support
Use of funds
- 01Continue product development
- 02Scale operations
Investors
Categories
About the company
52 North Health
52 North Health develops portable diagnostic devices to improve care for cancer patients.